RLMD Stock Risk & Deep Value Analysis
Relmada Therapeutics Inc
DVR Score
out of 10
What You Need to Know About RLMD Stock
We analyzed Relmada Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RLMD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
RLMD Risk Analysis & Red Flags
What Could Go Wrong
The single biggest risk is clinical trial failure for NDV-01. If the ongoing registrational trials for NDV-01 for high-risk NMIBC fail to meet primary endpoints (e.g., complete response rate, duration of response) or show unexpected safety concerns, the company's valuation, currently based on this asset, would plummet, potentially jeopardizing the entire $0.74B market cap.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Pre-revenue status and widening net losses: Net loss increased by 8.8% YoY to $19.1M in Q1 2026, indicating continued cash burn without an immediate revenue offset.
- ⚠
Reliance on single lead asset (NDV-01): The entire 10x thesis hinges on NDV-01's success, making the company highly susceptible to a single point of failure in clinical trials.
- ⚠
Share dilution from PIPE financing: The S-3 registration for resale of 29,474,569 shares (plus warrants) from the $160M PIPE financing indicates potential future selling pressure from these investors.
Upcoming Risk Events
- 📅
Q2 2026 earnings (estimated early August 2026): A significant increase in cash burn (e.g., >$25M/quarter) could signal a shorter cash runway than anticipated.
- 📅
Delayed initiation of NDV-01 Phase 3 trial beyond Q1 2027: Operational setbacks could push back timelines, impacting valuation expectations.
- 📅
Negative feedback from FDA regarding NDV-01 trial design or registrational pathways (Ongoing): Adverse guidance could necessitate trial changes or increase regulatory hurdles.
When to Reconsider
- 🚪
Exit if NDV-01 Phase 3 trial initiation is delayed beyond Q1 2027, indicating significant operational setbacks.
- 🚪
Sell if cash and equivalents drop below $100M without secured additional financing, signaling a critically shortened cash runway.
- 🚪
Exit if NDV-01 registrational trial results show efficacy significantly below the 70% 12-month CR previously observed in Phase 2, or new serious safety signals emerge.
Unlock RLMD Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If NDV-01 successfully navigates its registrational Phase 3 trials for high-risk NMIBC, delivering efficacy and safety consistent with its strong Phase 2 data (e.g., 70%+ 12-month CR), and secures FDA approval within 3-5 years, then the company can capture a significant share of the underserved NMIBC market, driving peak annual sales of $500M-$1B. This would re-rate RLMD to a multi-billion dollar market cap (e.g., $3B-$5B at 3-5x P/S), representing a 4-7x increase from its current $0.74B valuation. This is bullish because the market currently prices the clinical risk heavily, underestimating the commercial potential of a de-risked asset with a clear unmet need.
Is RLMD Stock Undervalued?
Unlock the full AI analysis for RLMD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RLMD Price Targets & Strategy
12-Month Target
$15.00
Bull Case
$70.40
Bear Case
$5.00
Valuation Basis
Represents a ~1.5x premium over median analyst targets, reflecting significant de-risking milestones (e.g., Phase 3 initiation, interim data for NDV-01) over the next 12 months, leading to an implied probability-adjusted NPV of ~$1.5B by mid-2027.
Entry Strategy
Consider initiating a position near the current price of $7.04, or on any dips towards $6.50, establishing a baseline ahead of key clinical catalysts.
Exit Strategy
Take partial profit at $15.00, scale out further towards $30.00 and $70.40 as clinical and commercial milestones are met. Implement a stop-loss order if the price consistently trades below $5.00, signaling a potential failure in key clinical programs.
Portfolio Allocation
7-15% for aggressive risk tolerance, reflecting the high-risk, high-reward nature of a clinical-stage biotech dependent on a single lead asset.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is RLMD Financially Healthy?
Valuation
P/E Ratio
-6.46
Profitability
Return on Equity
-71.22%
EPS
$-1.15
Balance Sheet
Current Ratio
14.62
Quick Ratio
14.46
Other
Beta (Volatility)
0.40
Does RLMD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is expanding as NDV-01 progresses through later-stage clinical trials. Its durability will hinge on successful commercialization, continued patent protection, and market adoption without significant competition emerging with superior efficacy or safety profiles.
Moat Erosion Risks
- •Clinical trial failure: Failure of NDV-01 in Phase 3 trials would instantly eliminate the primary source of the moat.
- •Emergence of superior competing therapies: Other companies developing novel treatments for NMIBC could challenge NDV-01's market position post-approval.
- •Patent expiry or challenges: Loss of patent protection could open the door to generic competition, eroding market share and pricing power.
RLMD Competitive Moat Analysis
Sign up to see competitive advantages
RLMD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No specific data provided, but clinical-stage biotechs can generate significant retail interest around trial updates).
Institutional Sentiment
Positive (3 Buy/Outperform ratings, 0 Sell ratings, with a median price target of $12.0 and a high of $19.0).
Insider Activity (Form 4)
No verified Form 4 activity provided in the last 90 days, suggesting no significant recent buying or selling by key executives.
Options Flow
Normal options activity (No specific data indicating unusual put/call ratio or large institutional block trades).
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026 results)
Surprise Probability
Medium (While EPS misses are common for pre-revenue biotechs, the focus will be on R&D spend and clinical updates rather than revenue figures).
Historical Earnings Pattern
For clinical-stage biotechs, stock price reactions are typically more driven by significant clinical or regulatory news (e.g., trial results, FDA decisions) rather than minor EPS beats or misses.
Key Metrics to Watch
Competitive Position
Top Competitor
JNJ (Johnson & Johnson, or other large pharma with oncology pipeline, as potential acquirer or partner)
Market Share Trend
Not applicable; company is pre-revenue and has no current market share.
Valuation vs Peers
As a pre-revenue clinical-stage biotech, RLMD's valuation is primarily pipeline-driven, making direct comparison to revenue/earnings-based multiples of commercial-stage peers difficult. Its current market cap of $0.74B is largely based on the perceived value and probability of success of NDV-01.
Competitive Advantages
- •Strong Phase 2 data for NDV-01 (95% CR, 76% 12-month CR) in a high-risk, underserved NMIBC population.
- •Positive FDA feedback supporting two registrational pathways, potentially accelerating time to market and de-risking regulatory hurdles.
- •Potential for first-in-class or best-in-class therapy in BCG-unresponsive NMIBC, addressing a significant unmet medical need.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive RLMD Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 earnings report (estimated early August 2026): Key update on NDV-01 Phase 3 trial initiation progress and cash burn outlook.
- •Initiation of registrational Phase 3 clinical trial for NDV-01 in high-risk NMIBC (expected H2 2026): Formal announcement of patient enrollment and trial design will validate pathway.
Medium-Term (6-18 months)
- •End-of-Phase 2/Pre-Phase 3 meeting with FDA for a second registrational pathway for NDV-01 (mid-2027): Clarification and alignment on the second path will broaden market potential.
- •Interim data readout or Data Safety Monitoring Board (DSMB) review of NDV-01 Phase 3 trial (Q4 2027/early 2028): Positive early signals on efficacy or safety would significantly de-risk the asset.
Long-Term (18+ months)
- •Completion of NDV-01 Phase 3 clinical trial and announcement of top-line results (2028-2029): Positive data is crucial for FDA filing and could drive a re-rating to multi-billion dollar valuation.
- •FDA approval and commercial launch of NDV-01 for NMIBC (2029-2030): Successful market entry could lead to peak annual sales of $500M-$1B, justifying a $3B-$5B market cap.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for RLMD?
- ✓
Monitor NDV-01 Phase 3 trial initiation progress and interim data readouts; positive news on these fronts would signal significant de-risking and potential for valuation upside.
- ✓
Observe any new competition entering the BCG-unresponsive NMIBC space that could challenge NDV-01's potential market share or pricing power.
- ✓
Track the cash burn rate; a significant increase beyond current projections (e.g., >$25M/quarter) without additional financing would indicate increasing financial risk.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Relmada Therapeutics Inc Makes Money
Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies, primarily for high-risk non-muscle invasive bladder cancer (NMIBC) with its lead candidate, NDV-01. The company currently generates no revenue and operates by securing capital through equity financing (such as its recent $160 million PIPE) to fund extensive research and development activities and expensive clinical trials. Its long-term business model hinges entirely on successfully advancing NDV-01 through regulatory approval processes, after which it plans to generate revenue from the commercial sales of the drug, potentially through its own sales force or by partnering with larger pharmaceutical companies for distribution.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Relmada Therapeutics Inc (RLMD)?
As of May 24, 2026, Relmada Therapeutics Inc has a DVR Score of 8.3 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Relmada Therapeutics Inc?
Relmada Therapeutics Inc's market capitalization is approximately $738.4M..
What is the risk level for RLMD stock?
Our analysis rates Relmada Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RLMD?
Relmada Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -6.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the RLMD DVR analysis updated?
Our AI-powered analysis of Relmada Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RLMD (Relmada Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.